Jenavalve Technology, Inc.
$869.0K 185 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
International Life Sciences
International Life Sciences reported $883,786.29 across General Payments, Research, and Ownership to 535 physicians and teaching hospitals across 535 transactions.
- $883.8K Above-median payer
- All-tracks total
- 535 Above-median volume
- Transactions
- 535 Above-median reach
- Recipients
- −$355.0K
- General Payments vs PY2023
International Life Sciences reported $883,786.29 across all CMS Open Payments tracks (General + Research + Ownership) to 535 physicians and teaching hospitals in Program Year 2024 - ranking #647 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $883,786.29, averaging $1.7K per recipient.
International Life Sciences's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
24/100
Total payments
F
18/100
Transaction volume
F
14/100
Physician reach
F
14/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer international-life-sciences International Life Sciences
$883.8K · #647/1,925 · 0.0% industry · PY2024
- TOT $883.8K
- RANK #647
- SHARE 0.0%
- TXN 535
- RCP 535
- CAT 4
- GEN $883.8K
- ΔGEN −$355.0K
- TOP1 9.1%
- PY 2024
Volume peers
Nearest volume peer: Jenavalve Technology, Inc. ($869.0K)
International Life Sciences sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
International Life Sciences's CMS-reported General Payments decreased by $355.0K (−28.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: INTERNATIONAL LIFE SCIENCESPY2023: INTERNATIONAL LIFE SCIENCESPY2024: International Life Sciences. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,238,783.35
- PY2024
- $883,786.29
What the Data Shows for International Life Sciences
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For International Life Sciences that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Royalty or License" at $433.5K, accounting for 49.1% of this company's General Payments and 18 transactions.
General Payment Breakdown by Type
International Life Sciences made 4 types of general payments. "Royalty or License" is the largest category at $433.5K, 49.1% of General Payments.
International Life Sciences reports 4 general-payment categories - the top three are Royalty or License (49.1%), Consulting Fee (43.2%), and Travel and Lodging (5.4%). The remaining 1 category make up 2.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How International Life Sciences divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $433.5K | 18 | 49.1% |
| Consulting Fee | $381.9K | 120 | 43.2% |
| Travel and Lodging | $47.9K | 177 | 5.4% |
| Food and Beverage | $20.5K | 220 | 2.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $333,686.26 (37.8%) of $883,786.29 in this company's General Payments records across 272 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for International Life Sciences
The five named recipients with the highest reported General Payments from this company
- 1
Jesse Doty
$80,562.53 across 24 reported transactions
- 2
Ryan Scott
$69,915.42 across 16 reported transactions
- 3
Steven Neufeld
$65,925.06 across 12 reported transactions
- 4
John Ellington
$59,570.42 across 7 reported transactions
- 5
Robert Anderson
$57,712.83 across 7 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
International Life Sciences ranks #647 of 1,925 by total payments (top 34% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,301 of 1,838 by HHI (bottom 29% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Iovance Biotherapeutics, Inc. : $114.7K total payments, HHI 489
- Arjo Inc. : $151.8K total payments, HHI 489
- Banner Life Sciences, LLC : $82.4K total payments, HHI 487
- FUJIFILM Sonosite, Inc. : $257.0K total payments, HHI 486
- restor3d, inc. : $1.6M total payments, HHI 486
- Micro-tech Endoscopy USA, Inc. : $159.3K total payments, HHI 483
- International Life Sciences (this company) : $883.8K total payments, HHI 481
- Octapharma USA, Inc. : $1.0M total payments, HHI 480
- Alliance Medical : $6.2K total payments, HHI 480
- Kyocera Medical Technologies, Inc. : $689.6K total payments, HHI 480
- GC America Inc. : $524.2K total payments, HHI 479
- Align Technology, Inc. : $16.8M total payments, HHI 478
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as International Life Sciences's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about International Life Sciences.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with International Life Sciences.
Showing 6 of 1,924 companies with CMS-reported payment data.
Life Technologies Corporation
$868.1K 479 recipients
Compare payment profiles
Sanara MedTech Inc.
$866.5K 2,677 recipients
Compare payment profiles
Motiva USA, LLC
$901.6K 1,217 recipients
Compare payment profiles
L&k Biomed Co. , Ltd.
$864.8K 38 recipients
Compare payment profiles
Canary Medical USA LLC
$903.4K 38 recipients
Compare payment profiles
Put this to use
International Life Sciences ranks #647 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just International Life Sciences. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.